Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

Abstract

Interferon therapy for patients with HBV-related cirrhosis significantly decreased the HCC rate, especially in patients with a larger amount of serum HBV DNA. If interferon is administered properly for a selected group of patients, an effective strategy of cancer prevention can be achieved, even in patients with cirrhosis.